Displaying drugs 7026 - 7050 of 8267 in total
JTC-801 free base
An antagonist of nociceptin receptor and analgesic agent, evaluated for its use in cancer treatment.
Investigational
Matched Description: … An antagonist of nociceptin receptor and analgesic agent, evaluated for its use in cancer treatment. …
rAAV9-rsATP7A
A recombinant adeno-associated viral vector gene therapy under investigation for the treatment of Menkes disease.
Investigational
Matched Description: … A recombinant adeno-associated viral vector gene therapy under investigation for the treatment of Menkes …
Indopan
Indopan (alpha-methyltryptamine) is a stimulant and psychoactive drug which produces effects similar to 3,4-methylenedioxy-N-methylamphetamine (MDMA), despite being structurally dissimilar. It was developed in the 1960's by Upjohn with the intention for use as an antidepressant. In the 1990's, indopan became regulated as a Schedule I controlled substance in the United...
Experimental
Illicit
MEM 1414
MEM 1414 is a PDE4 inhibitor that is being evaluated for the treatment of Alzheimer’s disease. This drug candidate has completed Phase 1 clinical trials. MEM 1414 works by blocking phosphodiesterase, an enzyme that breaks down an important brain chemical, cyclic AMP. It appears to work in the area of...
Investigational
Matched Description: … It appears to work in the area of the brain where new memories are formed. ... MEM 1414 is a PDE4 inhibitor that is being evaluated for the treatment of Alzheimer’s disease. …
Sirna-027
Sirna-027 is a chemically modified short interfering RNA(siRNA) targeting Vascular Endothelial Growth Factor Receptor-1(VEGFR-1). VEGFR-1 is a key component of the clinically validated vascular endothelial growth factor (VEGF) pathway. Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. It is used to treat Macular...
Investigational
Matched Description: … Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. ... VEGFR-1 is a key component of the clinically validated vascular endothelial growth factor (VEGF) pathway …
Protocatechualdehyde
Also known as protocatechuic aldehyde, protocatechualdehyde is a naturally-occuring phenolic aldehyde that is found in barley, green cavendish bananas, grapevine leaves and root of the herb S. miltiorrhiza . Protocatechualdehyde possesses antiproliferative and pro-apoptotic properties against human breast cancer cells and colorectal cancer cells by reducing the expression of pro-oncogenes...
Experimental
Matched Description: … properties against human breast cancer cells and colorectal cancer cells by reducing the expression of ... naturally-occuring phenolic aldehyde that is found in barley, green cavendish bananas, grapevine leaves and root of …
Deracoxib
Deracoxib is a non-steroidal anti-inflammatory drug of the coxib class, used in veterinary medicine to treat osteoarthritis in dogs. It is sold in tablets, which have added beefy flavour to increase palatability. Deramaxx received FDA approval in August 2002 for "the control of post operative pain and inflammation associated with...
Vet approved
Matched Description: … Deracoxib is a non-steroidal anti-inflammatory drug of the coxib class, used in veterinary medicine to ... Deramaxx received FDA approval in August 2002 for "the control of post operative pain and inflammation …
NNZ-2591
NNZ-2591 (cyclo-L-glycyl-L-2-allylproline) is an investigational synthetic analog of cyclic glycine-proline (cGP), a breakdown product of human insulin-like growth factor 1 (IGF-1), that has been chemically modified to increase its half-life, stability, and oral bioavailability. It is currently under development by Neuren Pharmaceuticals for the symptomatic treatment of Angelman, Phelan-McDermid, and...
Investigational
Matched Description: … NNZ-2591 (cyclo-L-glycyl-L-2-allylproline)[A189390] is an investigational synthetic analog of cyclic ... glycine-proline (cGP), a breakdown product of human insulin-like growth factor 1 (IGF-1), that has been ... [L11106] It is currently under development by Neuren Pharmaceuticals for the symptomatic treatment of …
Rocatinlimab
Rocatinlimab is a subcutaneously administered anti-OX40 antibody developed for the treatment of moderate-to-severe atopic dermatitis. In clinical trials, it has shown significant efficacy and safety compared to a placebo. The drug works by targeting the OX40 receptor, which plays a role in the immune response associated with atopic dermatitis. Despite...
Investigational
Matched Description: … Despite its promising results, the long-term safety of rocatinlimab requires further investigation, as ... Rocatinlimab is a subcutaneously administered anti-OX40 antibody developed for the treatment of moderate-to-severe ... Additionally, the diverse genetic backgrounds of patients may influence the drug’s effectiveness and …
Sitamaquine
Sitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army Institute, in collaboration with GlaxoSmithKline (formerly SmithKline Beecham), for the potential treatment of visceral leishmaniasis.
Investigational
Matched Description: … Institute, in collaboration with GlaxoSmithKline (formerly SmithKline Beecham), for the potential treatment of …
GI-4000
A vaccine containing a heat-killed recombinant Saccharomyces cerevisiae yeast transfected with mutated forms of Ras, an oncogene frequently found in solid tumors, with potential immunostimulant and antitumor activity.
Investigational
Matched Description: … containing a heat-killed recombinant Saccharomyces cerevisiae yeast transfected with mutated forms of …
EGEN-001
EGEN-001 is a novel non-viral vector consisting of a plasmid DNA encoding the human gene for interleukin 12 (IL-12) and a biocompatible, biodegradable delivery polymer with potential antineoplastic activity.
Investigational
Matched Description: … EGEN-001 is a novel non-viral vector consisting of a plasmid DNA encoding the human gene for interleukin …
BMS-564929
BMS-564929 is an investigational therapeutic agent built to be a selective androgen receptor modulator (SARM). So far, it has been developed by Bristol-Myers Squibb for the symptomatic treatment of andropause.
Experimental
Matched Description: … So far, it has been developed by Bristol-Myers Squibb for the symptomatic treatment of andropause. …
Fluoromisonidazole F-18
Fluoromisonidazole F-18 is under investigation in clinical trial NCT01507428 (Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer).
Investigational
Matched Description: … Fluoromisonidazole F-18 is under investigation in clinical trial NCT01507428 (Study of Positron Emission …
CX-2009
CX-2009 is under investigation in clinical trial NCT03149549 (PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors).
Investigational
Matched Description: … investigation in clinical trial NCT03149549 (PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of …
OT-730
OT-730 is under investigation in clinical trial NCT00753168 (Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-angle Glaucoma).
Investigational
Matched Description: … OT-730 is under investigation in clinical trial NCT00753168 (Phase 1-2 Evaluation of OT-730 Eye Drops …
Tovinontrine
Tovinontrine is an orally administered, highly selective phosphodiesterase 9 (PDE9) small molecule inhibitor. Tovinontrine is under investigation in clinical trial NCT04474314 (A Study of IMR-687 in Subjects With Sickle Cell Disease).
Investigational
Matched Description: … Tovinontrine is under investigation in clinical trial NCT04474314 (A Study of IMR-687 in Subjects With …
TBX-3400
TBX-3400 is an investigational cell-based immunotherapy consisting of autologous peripheral blood mononuclear cells (PBMCs) treated ex vivo with TBX-4000, which is a recombinant TAT-MYC fusion protein.[L44281,L44286]
Investigational
Matched Description: … TBX-3400 is an investigational cell-based immunotherapy consisting of autologous peripheral blood mononuclear …
DCVAC/OvCa
DCVAC/OvCa is a therapy comprising autologous dendritic cells pulsed with killed ovarian cancer cells and matured by TLR3 ligand ex vivo. It is under investigation for the treatment of ovarian cancer.
Investigational
Matched Description: … It is under investigation for the treatment of ovarian cancer. …
Zilebesiran
Zilebesiran is under investigation in clinical trial NCT06272487 (Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)).
Investigational
Matched Description: … Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of …
Batroxobin
Batroxobin is a defibrinogenating hemostatic agent derived from the venom of a pit viper, Bothrops atrox moojeni. In addition to batroxobin, the venom of Bothrops atrox has a composition of 10.2% neutral carbohydrate. Batroxobin is a serine protease, which cleaves the 16 Arginine - 17 Glycine bond in fibrinogen. The...
Experimental
Matched Description: … In addition to batroxobin, the venom of Bothrops atrox has a composition of 10.2% neutral carbohydrate ... The MW of batroxobin is approximately 43,000 g/mol-1, and it contains 231 amino acids. ... Batroxobin is a defibrinogenating hemostatic agent derived from the venom of a pit viper, Bothrops atrox …
9,10-Deepithio-9,10-Didehydroacanthifolicin
A specific inhibitor of phosphoserine/threonine protein phosphatase 1 and 2a. It is also a potent tumor promoter. (Thromb Res 1992;67(4):345-54 & Cancer Res 1993;53(2):239-41)
Experimental
Matched Description: … A specific inhibitor of phosphoserine/threonine protein phosphatase 1 and 2a. …
MN-305
MN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by MediciNova for the treatment of anxiety disorders beginning with Generalized Anxiety Disorder (GAD).
Investigational
Matched Description: … highly selective serotonin 5-HT1A receptor agonist under development by MediciNova for the treatment of …
BI-K0376
BI-K0376 is investigated for use/treatment in acne. BI-K0376 is a solid. It is under investigation by Pfizer and has gone through phase I of the clinical trails.
Investigational
Matched Description: … It is under investigation by Pfizer and has gone through phase I of the clinical trails. …
Sotrastaurin
Sotrastaurin has been used in trials studying the basic science and treatment of Uveal Melanoma, Richter Syndrome, Prolymphocytic Leukemia, Recurrent Mantle Cell Lymphoma, and Recurrent Small Lymphocytic Lymphoma, among others.
Investigational
Matched Description: … Sotrastaurin has been used in trials studying the basic science and treatment of Uveal Melanoma, Richter …
Displaying drugs 7026 - 7050 of 8267 in total